Pharmacy Prior Authorization

AETNA BETTER HEALTH ILLINOIS FAMILY HEALTH PLAN (MEDICAID)

Aranesp (Medicaid)

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to Aetna Better Health Illinois at **1-844-242-0908**.

When conditions are met, we will authorize the coverage of Aranesp (Medicaid).

Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise.

Drug Name (please circle)			
Aranesp (darbepoetin alfa)			
Other, please specify			
Quantity	Frequency Strength		
Route of Administration	Expected Length of therapy		
Patient Information			
Patient Name:			
Patient ID:			
Patient Group No.:			
Patient DOB:			
Patient Phone:			
Prescribing Physician			
Physician Name:			
Specialty:	NPI Number:		
Physician Fax:	Physician Phone:		
Physician Address: City, State, Zip:			
Diagnosis:	ICD Code:		
Please circle the appropriate answer	er for each question.		
Has this plan authorized previous authorization is	this medication in the past for this patient (i.e., on file under this plan)?	Y	N
[If yes, skip to question 1	0.]		
evidenced by one of the equal to 100 ng/ml and trathan or equal to 20%, or	dequate iron stores to support erythropoiesis as following: A) Serum ferritin greater than or ansferrin saturation (iron saturation) greater B) Normal serum iron, TIBC and serum ferritin, globin content (CHr) greater than 29	Y	N
Please document Iron St	rudies obtained, results, and date drawn:		

Reference Number: C4911-A / Effective Date: 06/16/2017

	[If no, then no further questions.]		
3.	Does the patient have uncontrolled high blood pressure?	Υ	N
	[If yes, then no further questions.]		
4.	Does the patient have a diagnosis of anemia due to chronic kidney disease?	Υ	N
	[If no, skip to question 6.]		
5.	Does the patient have hemoglobin less than 10 g/dL within 2 weeks prior to initiating therapy?	Υ	N
	Please document hemoglobin and date drawn:		
	[If no, then no further questions.]		
	[If yes, skip to question 9.]		
6.	Is therapy requested for the treatment of anemia in a cancer patient?	Y	N
	[If no, then no further questions.]		
7.	Is the patient currently receiving chemotherapy?	Y	N
	[If no, then no further questions.]		
8.	Does the patient meet all of the following conditions for approval: A) Hemoglobin less than 10 g/dL within the 2 weeks prior to starting therapy, B) Diagnosis of non-myeloid malignancy (e.g., solid tumor), and C) Patient will receive chemotherapy for at least 2 additional months	Υ	N
	Please document hemoglobin and date drawn:		
	[If no, no further questions.]		
9.	Has the patient experienced treatment failure or intolerable side effects with Epogen and Procrit?	Υ	N
	[No further questions.]		
10	. Does the patient have hemoglobin less than 11 g/dL within the last 2 weeks?	Υ	N
	Please document hemoglobin and date drawn:		
	[If no, no further questions.]		

Reference Number: C4911-A / Effective Date: 06/16/2017

Prescribe	er (Or Authorized) Signature	Date		
I affirm that	the information given on this form is true and accurate as of this da	ate.		
Comme	•			
	urther questions.]			
(e.g., 20%)	, serum ferritin above 100ng/mL, transferrin saturation above	15	Ĭ	IN
11. Does	s the patient have adequate iron stores to support erythropoies	is `	Y	Ν

Reference Number: C4911-A / Effective Date: 06/16/2017